Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.74 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.74 |
| ▸ | CHRNG | P07510 | 5/20 | 0.74 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.74 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.74 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.74 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.74 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.74 |
| ▸ | CHRND | Q07001 | 5/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.74 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | HRH1 | P35367 | 1/20 | 0.74 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955630 | 1.00 | CYP2B6 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL29486913 | 1.00 | CYP2B6 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL2955633 | 1.00 | CYP2B6 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL29564521 | 0.91 | CYP2B6 (0.83) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL15478523 | 0.89 | CYP2B6 (0.80) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| Bupropion SCHEMBL38777 | 0.85 | SLC6A3 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| Bupropion SCHEMBL29354885 | 0.85 | SLC6A3 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| Bupropion SCHEMBL29424575 | 0.85 | SLC6A3 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| Bupropion SCHEMBL300444 | 0.85 | SLC6A3 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG | |
| Bupropion SCHEMBL12499296 | 0.85 | SLC6A3 (1.00) | CYP2B6SLC6A2SLC6A3CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283334-A1 | Treatment of Viral Infections | BIOCOPEA, LTD. (GB) | 2012-11-08 | — | — | US | claimed |
| EP-2464345-A2 | TREATMENT OF VIRAL INFECTIONS | Biocopea Limited (GB) | 2012-06-20 | — | — | EP | claimed |
| WO-2011018653-A2 | TREATMENT OF VIRAL INFECTIONS | BIOCOPEA LIMITED (GB) | 2011-02-17 | — | — | WO | claimed |
| CN-117100750-A | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114340608-B | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116459255-A | Use of deuterated dextromethorphan and bupropion in combination in preparation of AD (analog to digital) excitation drugs | 深圳信立泰药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-114340608-A | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022017300-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
| US-8653271-B2 | Enhancing transdermal delivery of opioid antagonists and agonists using codrugs linked to bupropion or hydroxybupropion | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120283334-A1 | Treatment of Viral Infections | BIOCOPEA, LTD. (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| EP-1993525-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-20080008754-A1 | Pharmaceutical Compositions Comprising (+)-(2S,3S)-2-(3-Chlorophenyl)-3,5,5-Trimethyl-2-Morpholinol | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080008754-A1 | Pharmaceutical Compositions Comprising (+)-(2S,3S)-2-(3-Chlorophenyl)-3,5,5-Trimethyl-2-Morpholinol | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007102008-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007102008-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
| US-20070093486-A1 | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof | SMITH KLINE BEECHAM CORPORATION ,CORPORATION | 2007-04-26 | — | — | US | disclosed |
| US-20070093486-A1 | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof | SMITH KLINE BEECHAM CORPORATION ,CORPORATION | 2007-04-26 | — | — | US | disclosed |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, HRH2 | CYP2B6 907/4885SLC6A2 2156/4885SLC6A3 3254/4885 |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | METTL3, TPMT, MTAP | CYP2B6 196/4885SLC6A2 236/4885SLC6A3 115/4885 |
| US-20080008754-A1 | Pharmaceutical Compositions Comprising (+)-(2S,3S)-2-(3-Chlorophenyl)-3,5,5-Trimethyl-2-Morpholinol | MCOLN3, MCOLN2, LIPA | CYP2B6 192/4885SLC6A2 491/4885SLC6A3 620/4885 |
| US-20120283334-A1 | Treatment of Viral Infections | ELANE, EPX, MAVS | CYP2B6 563/4885SLC6A2 2689/4885SLC6A3 3514/4885 |
| US-20070093486-A1 | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof | MTAP, RNGTT, SPR | CYP2B6 119/4885SLC6A2 1202/4885SLC6A3 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.